Résultats de la recherche
10
Tout
Rechercher les filtres
Organisation
Tevogen Bio Inc
Tevogen Bio CEO Named to NJBIZ 2025 Health Care Power List as Company Advances Commercialization; Reaffirms Timeframe on Previously Announced Forecast
26 mars 2025 15h12 HE
|
Tevogen Bio Inc
WARREN, N.J., March 26, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech company leveraging AI-driven...
Tevogen Bio Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization Plan
25 mars 2025 13h11 HE
|
Tevogen Bio Inc
WARREN, N.J., March 25, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech company leveraging...
Tevogen Bio Announces Unique T Cell Vaccine Under Development and Files Patent with the USPTO
10 mars 2025 12h40 HE
|
Tevogen Bio Inc
Vaccine is intended to stimulate T cell responses against targets across the entire genome of the selected virus, similar to company’s lead product candidate TVGN 489, to mitigate the risk posed by...
Tevogen Bio’s CIO & Head of Tevogen.AI, Mittul Mehta, Featured Speaker at Proskauer’s AI Discussion Panel
07 mars 2025 16h09 HE
|
Tevogen Bio Inc
WARREN, N.J., March 07, 2025 (GLOBE NEWSWIRE) -- Mittul Mehta, Chief Information Officer & Head of Tevogen.AI at Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), a...
Tevogen Bio to Receive $8 Million of Non-Dilutive Grant Funding, Reiterates Efficient Operations
03 mars 2025 12h52 HE
|
Tevogen Bio Inc
Tevogen Bio will receive the remaining $8 million grant, totaling $10 million, from KRHP LLC this quarter, following a positive review of its progress, particularly in Tevogen.AI.Efficient operations...
Tevogen Bio Founder and CEO Dr. Ryan Saadi Named to 2025 NJBIZ Power 100, Celebrating Innovation and Leadership in Accessible T Cell Therapy
28 févr. 2025 13h17 HE
|
Tevogen Bio Inc
Tevogen Bio is focused on delivering affordable, safe, and easy-to-administer T cell therapies.The company’s ExacTcell™ technology enabled a proof-of-concept trial with highly positive results,...
Tevogen Bio’s First Trading Year Efficiency: 600% Higher Market Cap Per Team Member, 79% Insider-Owned
21 févr. 2025 15h28 HE
|
Tevogen Bio Inc
600% higher market cap per team member when compared to industry average. Source: Mr. Damodaran at the Stern School of Business at NYU.Current ownership breakdown: Insiders 79%; Independent Board...
Tevogen Bio CEO Reinforces Commitment to Retention of Equity Capital and Long-Term Vision
14 févr. 2025 18h31 HE
|
Tevogen Bio Inc
WARREN, N.J., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Ryan Saadi, MD, MPH, Founder and CEO of Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), a clinical-stage specialty...
Tevogen Bio Shares 2024 Financing Activity on One Year Anniversary of Becoming a Publicly Listed Company; Highlights Operational Efficiency
14 févr. 2025 13h16 HE
|
Tevogen Bio Inc
WARREN, N.J., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech company, shares a summary of...
Tevogen Bio CEO Addresses Short Selling and Its Potential Impact on the Nation’s Health and Prosperity
14 févr. 2025 11h52 HE
|
Tevogen Bio Inc
CEO of Tevogen Bio, Dr. Saadi addresses short selling and its potential impact on the nation’s health and prosperity. Reaffirms commitment to shareholders.